By Fineline Cube 
China-based 3D Medicines (HKG: 1244) announced a strategic collaboration with domestic gene sequencing specialist MGI Tech Co., Ltd. The partnership leverages their respective technological strengths in precision medicine to address global market demands.
Collaboration Framework
The two companies will focus on long-term, in-depth cooperation in oncology, infectious diseases, and other fields. The collaboration will primarily utilize MGI’s G99 gene sequencer to develop integrated precision testing solutions.
Integrated Solutions
The partners aim to promote comprehensive solutions covering the entire workflow, from sample extraction and library preparation to high-throughput sequencing and data analysis/interpretation. This integrated approach is designed to meet cutting-edge demands in precision medicine.-Fineline Info & Tech